Ország: Új-Zéland
Nyelv: angol
Forrás: Medsafe (Medicines Safety Authority)
Allopurinol 100mg;
Sandoz New Zealand Limited
Allopurinol 100 mg
100 mg
Tablet
Active: Allopurinol 100mg Excipient: Crospovidone Macrogol 4000 Magnesium stearate Microcrystalline cellulose Povidone Powdered cellulose Purified talc
Bottle, plastic, HDPE, 200 tablets, 200 tablets
Prescription
Prescription
Sicor (Societa Italiana Corticosteroidi) Srl
Package - Contents - Shelf Life: Bottle, plastic, HDPE bottle with child resistant closure - 200 tablets - 36 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE bottle with child resistant closure - 250 tablets - 36 months from date of manufacture stored at or below 25°C
1998-10-28
NEW ZEALAND DATA SHEET ALLOPURINOL SANDOZ ® _ALLOPURINOL PH EUR, TABLETS, 100 MG AND 300 MG _ PRESENTATION 100 MG White, round, plain, uncoated tablets, scored on one side. Each tablet contains allopurinol 100 mg. 300 MG White to off-white, 17 mm x 7 mm oblong, biconvex plain, uncoated tablets with a breaking notch on both sides. Each tablet contains allopurinol 300 mg. USES _ACTIONS _ Allopurinol is used to decrease uric acid concentrations in plasma and/or urine when hyperuricaemia is clinically significant. PHARMACOTHERAPEUTIC GROUP M04AA01 - Preparations inhibiting uric acid production, allopurinol. MECHANISM OF ACTION Allopurinol inhibits xanthine oxidase, the enzyme which catalyses the oxidation of hypoxanthine to xanthine, and of xanthine to urate/uric acid. PHARMACODYNAMIC EFFECTS Allopurinol and its main metabolite oxypurinol lower the level of uric acid in plasma and urine in two ways: the inhibition of xanthine oxidase reduces the amount of hypoxanthine and xanthine converted to urate/uric acid; this action, in some but not all hyperuricaemic patients, makes more hypoxanthine and xanthine available for reutilisation in the purine metabolic cycle, which in turn, depresses overall _de novo_ purine biosynthesis via feedback inhibition of hypoxanthine-guanine phosphorbosyltransferase. With the lowered urate/uric acid levels in serum and urine produced by allopurinol there are also increased levels of the substrates hypoxanthine and xanthine. Plasma concentrations of these oxypurines are only slightly increased and the rate and extent of their renal clearance is greater than that of uric acid. In the absence of allopurinol, normal urinary output of oxypurines is almost solely in the form of uric acid. After administration of allopurinol, it is composed of hypoxanthine, xanthine a Olvassa el a teljes dokumentumot